Now Reading: Free SMA drug Risdiplam to be available in all Kerala districts
-
01
Free SMA drug Risdiplam to be available in all Kerala districts
The Story in Brief
Kerala Health Minister K. Muraleedharan has announced that Risdiplam for spinal muscular atrophy (SMA) patients will be made available through medical colleges in all districts. The Additional Chief Secretary (Health) will coordinate the initiative, the minister said on Saturday, 7 November 2026. Currently, free medication is distributed only through SMA clinics at Thiruvananthapuram and Kozhikode Government Medical Colleges.
The Times of India reports that the medicines will be available at all government medical college hospitals by mid November 2026, dispensed through paediatric wings. Kerala Medical Services Corporation recently procured generic SMA drugs at lower prices, enabling wider access. While the government has decided to provide free medicines to all SMA patients irrespective of age, an expert panel will determine which patients above 18 are likely to benefit, and another panel will assess suitability before administration. The minister said steps have been initiated to remove the age restriction for free medication, currently limited to patients up to 12 years of age.
Indian Opinion Analysis
The Hindu leads with the government's announcement and frames the expansion as a family-centred healthcare model, emphasising relief for parents who travelled long distances. The Times of India foregrounds the procurement of cheaper Indian generics and the conditionality of expert-panel assessment for patients above 18, and notes opposition criticism from the CPM. Where The Hindu omits any reference to generic-versus-branded tension or expert-panel gatekeeping, the Times reports both as substantive elements of the rollout. The balanced reading is that the government has committed to wider access but has simultaneously introduced expert evaluation for older patients, and that the use of generics, while enabling affordability, has drawn political criticism. The Times of India reports that an expert panel will determine which patients above 18 are likely to benefit before the drug is administered.
Coverage: 2 sources, 2 neutral
Sources (2): thehindu.com (neutral report), timesofindia.indiatimes.com (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.
